{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Columvi"},{"type":"Synonym","name":"anti-CD20/CD3 bispecific monoclonal antibody RO7082859"},{"type":"CodeName","name":"RO7082859"},{"type":"CodeName","name":"RO 7082859"},{"type":"Synonym","name":"anti-CD20 x anti-CD3 bispecific monoclonal antibody RO7082859"},{"type":"CASRegistryName","name":"2229047-91-8"},{"type":"Synonym","name":"glofitamab"}],"definition":{"html":"A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab-gxbm binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.","text":"A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab-gxbm binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/glofitamab-gxbm","text":"Glofitamab-gxbm"},"nciConceptId":"C148486","nciConceptName":"Glofitamab","termId":792571,"name":"glofitamab-gxbm","firstLetter":"g","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"glofitamab"}],"links":null}